Gemigliptin/rosuvastatin

Drug Profile

Gemigliptin/rosuvastatin

Alternative Names: Rosuvastatin/gemigliptin; ZemiStatin

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LG Life Sciences
  • Developer LG Chem
  • Class Antihyperglycaemics; Fluorobenzenes; Piperidines; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action CD26 antigen inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dyslipidaemias; Type 2 diabetes mellitus

Most Recent Events

  • 09 Jun 2017 Efficacy and adverse events data from a phase III trial in Type-2 diabetes mellitus and Dyslipidaemias presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 25 Jul 2016 Phase III development is ongoing in South Korea (LG Life Sciences pipeline, July 2016)
  • 01 Mar 2016 LG Life Sciences completes a phase III trial in Dyslipidaemias and Type-2 diabetes mellitus in South Korea (NCT02126358)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top